Comparison
DSIP vs. Thymosin Alpha-1
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Healing
CAS no.
62568-57-4
62304-98-7
Molecular weight
848.81 g/mol
3108.32 g/mol
Half-life
0.1 h
2 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluAc-SDAAVDTSSEITTKDLKEKKEVVEEAENMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Thymosin Alpha-1
Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
1
2
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
1